The invention relates to a new method for increasing proliferation rate of chondrocytes. The present invention is applicable both in research and medicine among others to improve proliferation of chondrocytes without affecting their differentiation status.

The described invention provides a method of functionally reprogramming adult cells to an immature cell type that expresses one or more embryonic biomarkers. The reprogramming is accomplished by contacting the adult cells with a platelet rich fraction comprising platelet-like cells from umbilical cord blood or peripheral blood, and expanding the immature cell type in vitro under culture conditions to generate an insulin-producing cell population that expresses human beta-cell specific transcription factors and is functionally equivalent to human pancreatic beta-cells. Without being limited by theory, platelet-like cells and their released mitochondria display immune tolerance-associated markers that may modulate the function and differentiation of immune cells. The described invention further provides a pharmaceutical composition comprising a cell product containing a therapeutic amount of an insulin-producing cell population derived from functionally reprogrammed adult cells, wherein the insulin-producing cell population expresses human beta-cell specific transcription factors and is functionally equivalent to human pancreatic beta-cells.

Provided herein are systems and methods for molecule delivery into cells. The method may include steps of forming a solution comprising an amount of microbubbles, an amount of soluble molecules, and one or more cells, flowing the solution through a microfluidic device, and sonicating the solution for a period of time sufficient to form pores in the one or more cells. In particular, such methods may be used for preservation of cells through delivery of a preservation agent.

The invention relates to progenitor cells of mesodermal lineage and their use in therapy.

The invention relates to progenitor cells of mesodermal lineage and their use in therapy.

The present disclosure relates to methods, cell culture medium and compositions that promote cell proliferation during fetal bovine serum free cell culture.

Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions, and the use of compositions containing platelet-rich plasma to accelerate or complete the differentiation of a cell line. Particularly, use of platelet-rich plasma in conjunction with cell differentiation.

Disclosed are angiogenesis stimulatory mesenchymal-like cells derived from menstrual blood, originating from endometrium and expressing increased levels of the protein CD39 as compared to other cells found from the menstrual blood. In one embodiment, menstrual blood mononuclear cells are plated on adherent culture and allowed to grow in a manner permitting expansion of mesenchymal-like cells. Said expanded cells are selected for expression of CD39 and utilized for stimulation of angiogenesis. In other embodiments, menstrual blood derived adherent cells are cultured with platelet derived factors in order to augment angiogenic ability, directly, or through upregulation of CD39 expression.

A composition and in vitro method for generating a desired cell type and/or tissue type from hair follicular stem cells. The composition and in vitro method are particularly suitable for generating an autologous desired cell type and/or tissue type. Furthermore, the composition and method are especially efficient and suitable for use in the context of cosmetic cell and/or tissue transplantation in recipient areas of a subject experiencing cell and/or tissue loss caused by, for example, a wound, scar, burn injury, tissue degeneration, and aging. The composition and in vitro method are also suitable to circumvent complications related to infections and/or immune rejection of a cosmetic cell and/or tissue implant or graft.

Platelet lysate compositions and cell culture media compositions for maintaining and/or growing mammalian cells, such as mammalian endothelial cells (ECs) and mammalian endothelial progenitor cells (EPCs), in particular human ECs (huECs) and human EPCs (huEPCs), such as primary huECs and primary huEPCs, are provided. The cell culture media compositions contain a basal medium, a platelet lysate and, optionally, one or more exogenously added growth factors. Also provided are methods for making and using such cell culture media compositions to grow and/or maintain ECs and EPCs, including huECs and huEPCs, as well as cell culture vessels, dishes, plates, and/or flasks pretreated with the cell culture media compositions.